GlassScriptPhysician profile
Philip S Becker
NPI 1679556765
$94,234.94
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,124 · 2020: $32K · 2021: $47K · 2022: $11K · 2023: $1,095 · 2024: $36.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087 · Education: $44.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.90 |
| Education | $44.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,277.56 | 2021-2024 | |
| Allergan, INC. | $35,866.80 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $4,140.89 | 2021 | |
| Genzyme Corporation | $677.70 | 2019-2023 | |
| Biogen, INC. | $431.87 | 2019-2023 | Vumerity |
| Acadia Pharmaceuticals INC | $408.38 | 2019-2023 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $322.05 | 2019-2023 | Austedo Xr |
| Ucb, INC. | $282.32 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $272.74 | 2019 | |
| Acorda Therapeutics, INC | $245.18 | 2019-2020 | |
| Sk Life Science, INC. | $234.10 | 2021-2023 | Xcopri |
| Sunovion Pharmaceuticals INC. | $188.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $157.27 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $146.45 | 2019 | |
| Mdd US Operations, LLC | $144.69 | 2020-2023 | Gocovri |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.